692 related articles for article (PubMed ID: 12775730)
1. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
[TBL] [Abstract][Full Text] [Related]
2. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
[TBL] [Abstract][Full Text] [Related]
4. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Kim GP; Sargent DJ; Mahoney MR; Rowland KM; Philip PA; Mitchell E; Mathews AP; Fitch TR; Goldberg RM; Alberts SR; Pitot HC
J Clin Oncol; 2009 Jun; 27(17):2848-54. PubMed ID: 19380443
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
6. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of oxaliplatin in the management of colorectal cancer.
de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Giantonio BJ; Catalano PJ; Meropol NJ; O'Dwyer PJ; Mitchell EP; Alberts SR; Schwartz MA; Benson AB;
J Clin Oncol; 2007 Apr; 25(12):1539-44. PubMed ID: 17442997
[TBL] [Abstract][Full Text] [Related]
11. [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
Tournigand C; de Gramont A
Bull Cancer; 2006 Feb; 93 Suppl 1():S11-5. PubMed ID: 16483941
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
13. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
Colucci G; Gebbia V; Paoletti G; Giuliani F; Caruso M; Gebbia N; Cartenì G; Agostara B; Pezzella G; Manzione L; Borsellino N; Misino A; Romito S; Durini E; Cordio S; Di Seri M; Lopez M; Maiello E; Montemurro S; Cramarossa A; Lorusso V; Di Bisceglie M; Chiarenza M; Valerio MR; Guida T; Leonardi V; Pisconti S; Rosati G; Carrozza F; Nettis G; Valdesi M; Filippelli G; Fortunato S; Mancarella S; Brunetti C;
J Clin Oncol; 2005 Aug; 23(22):4866-75. PubMed ID: 15939922
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
[TBL] [Abstract][Full Text] [Related]
18. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Rougier P; Lepille D; Bennouna J; Marre A; Ducreux M; Mignot L; Hua A; Méry-Mignard D
Ann Oncol; 2002 Oct; 13(10):1558-67. PubMed ID: 12377643
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
[TBL] [Abstract][Full Text] [Related]
20. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer.
Gholam D; Giacchetti S; Brézault-Bonnet C; Bouchahda M; Hauteville D; Adam R; Ducot B; Ghémard O; Kustlinger F; Jasmin C; Lévi F
Oncologist; 2006; 11(10):1072-80. PubMed ID: 17110626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
